Alopecia Areata is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Alopecia Areata have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Alopecia Areata compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alopecia Areata overview
Alopecia areata is an autoimmune condition characterized by unpredictable, patchy hair loss. It occurs when the immune system mistakenly attacks hair follicles, leading to hair loss in small, round patches on the scalp or other parts of the body. In some cases, it can progress to total hair loss (alopecia totalis) or loss of hair on the entire body (alopecia universalis). The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic, environmental, and autoimmune factors. It is thought that the immune activity leads to follicle shrinkage and the eventual interruption of hair growth. Alopecia areata typically presents as smooth, round patches of hair loss on the scalp. It can also affect other hair-bearing areas, such as eyebrows, eyelashes, or beard. In some cases, individuals may experience tingling or mild discomfort in the affected areas.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Alopecia Areata, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
